Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Quest Pen Broad Diagnostics Development Deal

NEW YORK, Oct. 18 – Roche Diagnostics and Quest Diagnostics have penned a deal to jointly develop gene-based tests to predict a person’s likelihood of developing particular diseases and to evaluate the best course of treatment.

The companies said they would work together to commercialize gene-based markers to determine a person’s risk for stroke or asthma.

The current deal may expand on Roche’s previous collaborations with companies such as Affymetrix and DeCode Genetics, the companies said.

In a statement released Wednesday, the companies said that Roche Diagnostics of Indianapolis would provide its polymerase chain reaction technology while Quest of Teterboro, NJ, would offer its clinical expertise.

"Our clinical expertise combined with Roche Diagnostics' research capability will expand access to PCR technology for millions of patients and their physicians," Kenneth Freeman, CEO of Quest Diagnostics, said in a statement.

The companies did not disclose the financial terms of the deal.

In addition to developing new tests, Quest Diagnostics, which uses Roche’s PCR technology in its HIV tests, said it would now also standardize its tests for Chlamydia trachomatis and Neisseria gonorrhea on Roche’s PCR platform. Quest said that these tests would be used across its 30 regional laboratories.

The companies will also consider developing assays for diseases including hepatitis C using Roche’s platforms.

"By combining our experience and resources, we expect to expedite the transition of genomic discoveries into effective diagnostic products,” Martin Madaus, CEO of Roche Diagnostics, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more